Stock Scorecard
Stock Summary for Evaxion Biotech A/S (EVAX) - $4.12 as of 4/26/2024 3:12:47 PM EST
Total Score
5 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for EVAX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for EVAX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for EVAX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for EVAX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for EVAX
Financial Details for EVAX
Company Overview |
|
---|---|
Ticker | EVAX |
Company Name | Evaxion Biotech A/S |
Country | USA |
Description | Evaxion Biotech A / S, a clinical-stage artificial intelligence and immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company is headquartered in Hoersholm, Denmark. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/29/2024 |
Stock Price History |
|
Last Day Price | 4.12 |
Last Day Price Updated | 4/26/2024 3:12:47 PM EST |
Last Day Volume | 0 |
Average Daily Volume | 41,099 |
52-Week High | 18.50 |
52-Week Low | 2.82 |
Last Price to 52 Week Low | 46.10% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 64.46 |
Sector PE | 56.64 |
5-Year Average PE | -11.33 |
Free Cash Flow Ratio | 3.85 |
Industry Free Cash Flow Ratio | 20.47 |
Sector Free Cash Flow Ratio | 30.65 |
Current Ratio Most Recent Quarter | 1.18 |
Total Cash Per Share | 1.07 |
Book Value Per Share Most Recent Quarter | -1.25 |
Price to Book Ratio | 7.59 |
Industry Price to Book Ratio | 7.85 |
Sector Price to Book Ratio | 22.15 |
Price to Sales Ratio Twelve Trailing Months | 292.90 |
Industry Price to Sales Ratio Twelve Trailing Months | 9.94 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
Total Shares Outstanding | 5,215,100 |
Market Capitalization | 21,486,212 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 4.36% |
Reported EPS 12 Trailing Months | -8.10 |
Reported EPS Past Year | -1.60 |
Reported EPS Prior Year | -2.26 |
Net Income Twelve Trailing Months | -22,162,042 |
Net Income Past Year | -22,159,054 |
Net Income Prior Year | -23,169,000 |
Quarterly Revenue Growth YOY | 0.00% |
5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 5,582,835 |
Total Cash Past Year | 5,582,835 |
Total Cash Prior Year | 13,184,000 |
Net Cash Position Most Recent Quarter | -2,906,165 |
Net Cash Position Past Year | -2,906,165 |
Long Term Debt Past Year | 8,489,000 |
Long Term Debt Prior Year | 7,864,000 |
Total Debt Most Recent Quarter | 8,489,000 |
Equity to Debt Ratio Past Year | -1.26 |
Equity to Debt Ratio Most Recent Quarter | -1.26 |
Total Stockholder Equity Past Year | -4,728,860 |
Total Stockholder Equity Prior Year | -72,659,000 |
Total Stockholder Equity Most Recent Quarter | -4,728,860 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | None |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.17 |
MACD Signal | 0.13 |
20-Day Bollinger Lower Band | 1.48 |
20-Day Bollinger Middle Band | 4.92 |
20-Day Bollinger Upper Band | 8.36 |
Beta | -0.02 |
RSI | 56.44 |
50-Day SMA | 8.59 |
200-Day SMA | 0.00 |
System |
|
Modified | 4/27/2024 12:04:55 AM EST |